ERBB2 and breast carcinoma: A distinctive feature is a higher correlation of its content with HER2-positive status and a low level of Ki-67 expression (Figure 5a and Figure 6), which, accordingly, determines a higher level of IL-6 in saliva in luminal B (HER2-positive) breast cancer.